Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Kayser S, Schliemann C, Kaufmann M, Kieser M, Platzbecker U, Müller-Tidow C, Schlenk RF. Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication. haematol [Internet]. 2026Aug.1 [cited 2026Aug.2];111(6):2114-7. Available from: https://haematologica.org/article/view/13000